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Sir,
 South Asian population is known to have an 
increased predisposition to type 2 diabetes mellitus 
(T2DM), which turns out to be an important health 
concern in this Region1. As per an earlier report about 
11.7 per cent people of Kolkata, West Bengal, suffered 
from T2DM and the prevalence was on a rise2. Anaemia 
is also present in the Region as a significant public 
health problem, having a prevalence of greater than 40 
per cent in South Asia3. However, the actual status of 
iron remains unclear because of extensive prevalence 
of haemoglobinopathies, possible genetic mutations 
contributing to iron overload, indiscriminate over-the-
counter use of iron pills and traditional formulations 
containing undefined concentrations of iron. Higher 
heme iron intake and increased body iron stores were 
found to be significantly associated with a greater risk of 
T2DM4,5. Patients suffering from haemoglobinopathies 
or undergoing repeated blood transfusions also suffer 
from secondary iron loading disorder6.
 Insulin influences the iron uptake and storage 
in cells by increasing the cell surface transferrin 
receptors7. Whether a patient with diabetes has excess 
iron due to increased insulin resistance still remains 
an unanswered question. Insulin resistance has been 
shown to have an association with chronic kidney 
diseases8,9. Iron accumulation has been reported in the 
proximal renal tubules in diabetic nephropathy10. Iron 
in its free form11,12 i.e. in non-transferrin bound form is 
known to induce oxidation of biomolecules and in the 
formation of reactive oxygen species. We, therefore, 
studied the free iron status in patients with T2DM and 
compared with healthy individuals and to find a suitable 
biocompatible reagent which can bind the free iron. 
 A cross-sectional, pilot study was conducted on 
consecutive patients attending the General Medicine 
outpatients department of M.R. Bangur Hospital, 
Kolkata, India, between August 2012 and February 
2014. Fasting blood and urine samples (10 ml each) 
were collected from 111 patients with T2DM (53.7 ± 
12.4 yr, M:F 60 : 51) and 30 healthy controls (75.6 
± 2.5 yr, M:F 8:7). Approval of ethical committee 
of Institute of Post Graduate Medical Education & 
Research (IPGMER), Kolkata, was obtained prior to 
the study. 
 Those (i) having anaemia, (ii) suffering from any 
form of haemoglobinopathy, (iii) who were on iron 
therapy within one year, (iv) having non-diabetic 
kidney disease, (v) having febrile illness, (vi) having 
benign prostatic hypertrophy or prostatic cancer, 
(vii) having urinary tract infection, or (viii) with 
uncontrolled hypertension, were excluded. The total 
iron analysis was done by Ferrozine method13 and free 
iron by HPLC14. Fasting plasma glucose was estimated 
by glucose oxidase-peroxidase (GOD-POD) method15, 
serum insulin by ELISA monobind kit and creatinine 
analysis was done by a kinetic assay15 of Jaffe’s involving 
alkaline solution of sodium picrate16. The plasma 
creatinine clearance or estimated glomerular filtration 
rate (eGFR) were estimated as per Cockroft and Gault 
formulae in ml/min17. Insulin resistance was calculated 
by homeostatic model assessment - insulin resistance 
(HOMA-IR) formula18. Urinary microalbumin analysis 
was done by immunoturbidimetry19.
 Conarachin I was extracted from peanut and 
purified20, and was used as a complexing agent for free 
iron. Conarachin I was characterized by molecular 
weight determination and absorption spectrometry20. 
A 15 per cent resolving sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) gel 
was used for molecular weight determination and 
confirmation of protein purification from crude peanut 
protein20. Presence of band at about 18 kD (Figure, 
lane 1) showed the presence of conarachin I in the 
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purified protein fraction as shown earlier19. Conarachin 
I (0.1 ml) was mixed with 0.4 ml of the diluted serum, 
injected to HPLC column and analyzed to compare 
the amount of free Fe2+ and Fe3+ of the same serum 
samples20.
 Qualitative data were grouped and compared by 
chi square test. Yates correction was done when the 
cell frequency was below five21. Quantitative data were 
subjected to comparison by their differences in mean 
by unpaired t test. A HOMA value of 2.4 was taken as 
comparator as the value exhibited evidence of diabetic 
kidney disease in an Indian study22. Serum iron value 
of 150 µg/dl was taken as upper reference limit for 
both sexes considering 145 and 160 as upper reference 
limit (URL) for females and males, respectively as per 
the kit insert.
 Insulin resistance was not found to be significantly 
associated with total iron. Serum total iron values <150 
and >150 µg/dl were compared with HOMA values 
<2.4 and >2.4 for both sexes. No association was seen 
when the means of total free iron were compared with 
HOMA<2.4 and HOMA>2.4 (15.7±1.64 vs16.02±2.56 
ppm); insulin resistance was not related to Fe3+/Fe2+ 
ratio either in males or in females. Obesity, as body 
mass index (BMI in kg/m2) >2523 was compared with 
HOMA, the association was significant at (P<0.01). 
Free iron has been known to cause damage by 
generation of free radicals. As obesity with raised 
amount of adipose tissue contributes to more serum 
iron and serum iron is known to contribute to insulin 
resistance, we decided to multiply the BMI with the 
ferric-ferrous ratio, and took the product (BMI×Fe3+/
Fe2+) as the index value. The median value of the 
distribution was around 0.37, the mode was 0.3, and 
HOMA was compared with values above and below 
0.3 in females and males.
 Iron contributes to insulin resistance (IR) by 
hindering its action on liver. It also retards the 
catabolism of insulin leading to hyperinsulinaemia. 
Insulin contributes to iron overload by generating 
more transferrin receptors, more ferritin and entry of 
iron into the fat cells24. So with more number of fat 
cells, more iron will be present in the body. This will 
contribute to insulin resistance. A significant difference 
was obtained in females (P<0.001) but not in males 
when the index was compared to HOMA of 2.4. Also, 
concordance of our index values between females and 
males showed significance (P<0.001) (Table I). Thus, 
one can assume that the product of free iron ratios and 
BMI bears a stronger association with IR in females 
than in males or BMI alone. A mean free iron value of 
15.82±1.38 ppm (n=111) was found in patients with 
diabetes, whereas it was 9.28±1.21 ppm in healthy 
controls (n=30) (P<0.001). 
 The stronger relationship with the index in females 
may be due to lesser amount of iron stores in them25. 
Ferric form contributes more to IR possibly as the 
origin of free iron is supposed to be from transferrin 
which contains iron in its ferric form. Ferric form may 
represent the initial active redox state of iron before 
being reduced to ferrous form. This led us to hypothesize 
that with more iron in ferric form, there would be more 
free iron turnover and hence more damage. Though 
higher amounts of both free and total iron were found 
amongst patients with microalbuminuria and lower 
eGFR, the results were not significant in our population 
which may be due to the presence of lesser amount of 
nephropathy in patients.
 Free iron was considerably reduced in the serum of 
most patients with diabetes upon addition of conarachin 
I with a few showing increase whereas serum samples 
of healthy subjects showed increase in the free iron 
concentration upon addition of conarachin I. The 
difference between the two groups was significant 
(P<0.001) (Table II). Patients with diabetes (mean 
fasting plasma glucose = 164.77±16.84 mg/dl) had a 
Figure. Purified conarachin I fraction along with its precursors 
subjected to sodium dodecyl sulphate - polyacrylamide gel 
electrophoresis (SDS-PAGE). Lane 1, pure conarachin 1; Lanes 2 
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higher level of free iron than healthy individuals possibly 
due to more generation of non-transferrin bound iron 
(NTBI) by glycation of apotransferrin which does not 
bind iron avidly26. It was interesting to observe that the 
higher plasma glucose level in patients with diabetes 
renders the medium reducing so as the initial Fe3+/Fe2+ 
equilibrium in plasma is maintained even after being 
exposed to aerial oxidation for up to 72 h27. The serum 
of patients with diabetes having higher mean fasting 
plasma glucose levels might enhance the complexing 
ability of conarachin I and reduce the free iron level. In 
healthy controls with normal glucose levels, addition 
of the protein conarachin I from outside probably 
disturbs the equilibrium of transferrin bound iron and 
releases some bound iron free thus increasing the free 
iron level. The results indicate that peanut proteins 
may serve to design therapeutics to reduce excess free 
iron in patients with diabetes and hence control sugar 
levels especially in insulin resistant female patients.
 In conclusion, free iron was significantly raised 
in serum of patients with T2DM when compared with 
healthy subjects. The calculated index of the product 
of BMI with the ferric-ferrous ratio may be important 
in assessing insulin resistance, particularly in females 
or BMI at any level of glycaemia. A peanut protein, 
conarachin I binds with the free iron in the serum 
of patients with diabetes and may contribute to the 
reduction of insulin resistance. The limitation of the 
study was that serum ferritin and total iron binding 
capacity (TIBC) were not measured. As serum ferritin 
is falsely raised in inflammatory states, thus may 
contribute as a confounding factor. The use of peanut 
protein to bind serum free iron is a subject of further 
investigations in animal models. 
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